Key Takeaways Pfizer's oncology gains from Seagen's ADCs but faces slowing sales and upcoming patent expirations.Bristol Myers expands its oncology reach with Mirati, RayzeBio, and Turning Point acquisitions.BMY oncology portfolio looks stronger, aided by new approvals like Opdivo, Qvantig and Augtyro.Pharma/biotech giants Pfizer (PFE) and Bristol Myers (BMY) boast a dominant position in the lucrative oncology space.Oncology or cancer is one of the most sought-after areas in the pharma/biotech space. As the ...